Kimberly-Clark (KMB) Q3 2026 (Q&A) earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 (Q&A) earnings summary
5 Nov, 2026Executive summary
Q3 net sales were $4.1B, down 0.4%; organic sales fell 1.3%, including a ~270 bps China social-media disruption headwind and North American retailer inventory pressure.
Adjusted operating profit declined 0.9% to $677M; adjusted continuing-operations EPS rose 17.2% to $1.70, while adjusted EPS attributable to Kimberly-Clark fell 6.6% to $1.70.
Kenvue acquisition closed November 2, 2026; integration is phased across first-100-day execution, establishing a foundation in 2027, then pursuing longer-term growth.
Financial highlights
Q3 adjusted gross margin was 35.5%, down 130 bps; pricing net of cost inflation and supply-chain investment pressured results, partly offset by productivity.
9M organic sales grew 0.3%; adjusted operating profit increased 3.0% to $2.166B and adjusted continuing-operations EPS rose 8.5% to $5.10.
9M adjusted free cash flow was $1.398B versus $1.263B; cash provided by operations, including discontinued operations, was $2.4B versus $1.8B.
Q3 net income was $1.8B versus $454M, primarily reflecting discontinued-operations income of $1.4B, including the IFP transaction gain.
Outlook and guidance
FY26 standalone outlook targets mid-single-digit constant-currency adjusted operating profit growth, high-single-digit adjusted continuing-operations EPS growth, and a low-single-digit decline in adjusted EPS attributable to Kimberly-Clark.
FY26 organic sales growth is expected to be ~100 bps below weighted-average market growth of ~1.7%; China disruption accounts for ~100 bps of total-company impact.
Adjusted free cash flow is expected to be ~$2B; capital expenditures ~$1.3B and adjusted tax rate ~23%.
FY27 adjusted EPS dilution is expected to be no more than mid-single digit versus standalone results; mid- to high-single-digit EPS CAGR is expected by year two of integration.
Deal accretion and ~2x leverage remain targeted by the end of the transaction’s second year; FY27 priorities include synergies, strengthening legacy businesses and targeted growth investment.
Latest events from Kimberly-Clark
- Adjusted EPS rose 17.2% as sales fell and Kenvue integration began.KMB
Q3 2026 Prepared Remarks - Consistent growth and margin gains continue, with Kenvue integration and Suzano JV driving future upside.KMB
Barclays 19th Annual Global Consumer Conference - Adjusted EPS up 10.4% in Q2 2026, but China disruption tempers full-year outlook.KMB
Q2 2026 Prepared Remarks - Adjusted EPS rose 10.4% in Q2 2026, but China disruption led to a cautious outlook.KMB
Q2 2026 (Q&A) - Acquisition targets $1.9B in synergies, leveraging complementary strengths for growth.KMB
Morgan Stanley Global Consumer & Retail Conference 2025 - A $48.7B merger forms a global health leader, targeting $2.1B in synergies by 2029.KMB
M&A Announcement - Q3 2024 delivered higher adjusted EPS and profit, reaffirming a strong 2024 outlook.KMB
Q3 2024 - Premiumization, innovation, and efficiency drive double-digit shareholder returns and growth.KMB
Deutsche Bank dbAccess 2024 Global Consumer Conference - 2025 targets volume-led growth, margin gains, and SG&A savings amid FX and divestiture headwinds.KMB
Q4 2024